Cancer Target: Mesothelin

Mesothelin is a glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein. Its biological function has not yet been clarified, but due to its limited distribution in normal tissues and high expression in some tumor tissues, it is expected to be used in tumor-specific treatment.
In existing studies of human epidermoid carcinoma cell lines expressing mesothelin, biodistribution analysis of mesothelin using radiolabeled monoclonal antibodies showed good localization and specificity for relevant tumors. So far, anti-mesothelin antibody-drug conjugates have been successfully used to treat mesothelin-expressing solid tumors, including ovarian cancer, pancreatic cancer, and malignant mesothelioma; and mesothelin targets chimeric antigen receptor (CAR) T cell therapy also showed significant antitumor effects. Therefore, targeted therapy and immunotherapy against mesothelin show promising application prospects.
Discussion Boards
- 120.1K All Discussion Boards
- 6 CSN Information
- 6 Welcome to CSN
- 120.3K Cancer specific
- 2.8K Anal Cancer
- 437 Bladder Cancer
- 302 Bone Cancers
- 1.6K Brain Cancer
- 28.3K Breast Cancer
- 384 Childhood Cancers
- 27.8K Colorectal Cancer
- 4.6K Esophageal Cancer
- 1.1K Gynecological Cancers (other than ovarian and uterine)
- 12.7K Head and Neck Cancer
- 6.3K Kidney Cancer
- 654 Leukemia
- 773 Liver Cancer
- 4.1K Lung Cancer
- 5K Lymphoma (Hodgkin and Non-Hodgkin)
- 228 Multiple Myeloma
- 7.1K Ovarian Cancer
- 39 Pancreatic Cancer
- 481 Peritoneal Cancer
- 5.1K Prostate Cancer
- 1.2K Rare and Other Cancers
- 528 Sarcoma
- 699 Skin Cancer
- 640 Stomach Cancer
- 190 Testicular Cancer
- 1.5K Thyroid Cancer
- 5.7K Uterine Cancer
- 6.2K Other Discussion Boards